About the Symposium

Launched in 2020 in response to the passage of Title V of the FDA Reauthorization Act, commonly known as the RACE for Children Act, the CureSearch Pediatric Early Development Symposium (PEDS) serves as an opportunity for industry, academia and regulatory leaders to examine the dynamic nature of clinical trials for a super rare population - children with cancer.

Each subsequent PEDS has built upon the last, returning participants to a mindset of advancing pediatric cancer clinical trials and exploring resources, infrastructure, collaborations and – in 2022 – technological integrations that make clinical trials for rare patient populations more robust and efficient. Register to join us here.

PEDS 2022: Leveraging Big Data to Advance Pediatric Clinical Trials

Big data technology is revolutionizing every aspect of our lives and healthcare is no different. Important efforts for improving clinical trials – especially in diseases with small patient populations – include global coordination, integration of innovations like decentralized infrastructure, real-world evidence and external controls. The only way to effectively coordinate and implement these strategies effectively is to engage technology in new ways. The 2022 PEDS will explore global technological efforts to improve clinical trial design and implementation. Using a robust interactive virtual platform, participants will be encouraged to discuss challenges and propose solutions to technology integration within their work and brainstorm opportunities to craft the future of clinical trials.

Symposium Co-Chairs

Jeffrey Skolnik, PhD

Jeffrey Skolnik, MD
Vice President,
Clinical Development
INOVIO Pharmaceuticals

Brenda Weigel

Brenda Weigel, MD
Director of the Division of
Pediatric Hematology/Oncology,
University of Minnesota's Masonic Cancer Center

Working Group Members

Elizabeth Fox, MD St. Jude Children's Research Hospital Memphis, TN
Elizabeth Fox, MD, MSc
Senior Vice President, Clinical Trials Research
St. Jude Children's Research Hospital
Gregory Reaman
Gregory Reaman, MD
Associate Director for Oncology Sciences
Center for Drug Evaluation & Research, U.S. FDA

Kannan Headshot 2020 (1)
Geoffrey Kannan, MD
Senior Mediacal Director
Labcorp Drug Development
Mark-Kieran-thumb
Mark Kieran, MD, PhD
Vice President of Clinical Development
Day One Biopharmaceuticals

Isaac R_C Headshot
Isaac Rodriguez-Chavez, PhD, MHSc, MSc
Senior Vice President, Scientific & Clinical Affairs
ICON plc

Attendees

Industry leaders, academics and other thought leaders in pediatric drug development.

- Medical Affairs
- Clinical Affairs
- Project Management
- Regulatory Affairs
- Research and Development
- Early Development
- Late Development

- Clinical Operations
- Executives
- Management
- Academic
- Patient Advocates
- Regulators
- Other key opinion leaders

Our

Sponsors

To learn more about becoming a sponsor for the 2022 Pediatric Early Development Symposium, please contact chris.riley@curesearch.org.

Pin It on Pinterest

Scroll to Top